Leadership at NuvOx Pharma

Executive Team

Evan Unger, MD

Co-Founder, Chief Executive Officer, and President

Dr. Unger has founded three biotech companies. His first company, ImaRx Pharmaceutical, developed 3 FDA approved drugs and was acquired by DuPont yielding a > 20x ROI. Dr. Unger’s second company, ImaRx Therapeutics, went public and performed clinical trials using a pioneering new technology to treat stroke. Dr. Unger co-founded NuvOx, in-licensed the core patents and obtained ownership of the regulatory documents for NuvOx’s key product. Dr. Unger is an inventor on over 120 issued US patents. He is a board-certified radiologist and is Professor Emeritus of Medical Imaging at the University of Arizona.

Rong Wang

Interim Chief Financial Officer / Chief Operating Officer 

Rong was trained as an engineer and received an MBA from University of Michigan. She has more than 20 years’ experiences in finance, operation, and business development, serving both public and private companies. She is passionate about the biotech/life science industry because of the noble causes and complexities. Excited by its impactful science and technology, Rong joined NuvOx to focus on both operation and finance.


Prior to NuvOx, Rong was an executive in investor backed companies and led multiple successful exits. Earlier in her career she also worked for Fortune 500 companies such as Ford (NYSE: F) and Baxter International (NYSE: BAX).

Kaitlin Graham, MS

Director of Clinical Science

Kaitlin received her M.Sc. in Biomedical Engineering from the University of Arizona. Her graduate research tested the use of targeted microbubbles as an early detection method for pancreatic cancer. She then transitioned into industry working under world-renowned microbubble expert, Dr. Evan Unger, to contribute to the development of NanO2 as a novel oxygen therapeutic. Kaitlin is the author of multiple peer-reviewed journal publications. Throughout her 5 years at NuvOx, Kaitlin has managed regulatory submissions, executed grant applications, and collaborated with project teams to develop clinical studies in several indications. 

Laurel Watkins de Jong, PhD

Director of Manufacturing 

Laurel joined NuvOx in August 2020 as the Director of Manufacturing. Prior to joining NuvOx, she received her PhD in Psychology/Neuroscience from the University of Milwaukee – Wisconsin. Laurel’s 12+ years of experience in laboratory research, ranging from molecular biology, to rodent neurophysiology, to human EEG recordings provide a unique background where she has participated in the creation of processes to validate data output for a wide range of data types and scientific questions. Since joining NuvOx, Laurel has focused on process optimization as the company progresses in the GMP manufacturing of NanO2.

Board of Directors

Evan Unger, MD

Dr. Unger has founded three biotech companies. His first company, ImaRx Pharmaceutical, developed 3 FDA approved drugs and was acquired by DuPont yielding a > 20x ROI. Dr. Unger’s second company, ImaRx Therapeutics, went public and performed clinical trials using a pioneering new technology to treat stroke. Dr. Unger co-founded NuvOx, in-licensed the core patents and obtained ownership of the regulatory documents for NuvOx’s key product. Dr. Unger is an inventor on over 120 issued US patents. He is a board-certified radiologist and is Professor Emeritus of Medical Imaging at the University of Arizona.

Jon Saxe, J.D., LL.M.

Jon S. Saxe, J.D., LL.M. spent almost 30 years with Hoffmann-LaRoche Inc. and is former Vice President of Licensing and Corporate Development and Head of Patent Law. From 1989 to 1993, he became president and CEO of Synergen Inc., a biotechnology company. As president of Saxe Associates from 1993 to 1995, he served as a consultant to venture capital firms and biotechnology, diagnostic, and pharmaceutical companies. From 1995 to 1999, he was president of PDL BioPharma.

 

Mr. Saxe currently serves as a director on the boards Vistagen Therapeutics (NASDAQ: VTGN) and Durect Corporation (NASDAQ: DRRX), and other companies. He has also served as a director of other biotechnology and pharmaceutical companies, including ID Biomedical (acquired by GlaxoSmithKline), Sciele Pharmaceuticals, Inc. (acquired by Shionogi), Amalyte (acquired by Kemin Industries), Cell Pathways (acquired by OSI Pharmaceuticals), Lumos Pharma, Inc. (merged with New Link Genetics) and other companies, both public and private. Mr. Saxe received his B.S. in chemical engineering from Carnegie Mellon University, his J.D. from George Washington University’s School of Law, and his LL.M. from New York University’s School of Law.

Richard Carmona MD, MPH, FACS

Richard Carmona MD, MPH, FACS was the 17th Surgeon General of the United States and is the Distinguished Professor of Public Health at the Mel and Enid Zuckerman College of Public Health. He also holds faculty appointments as a Professor of Surgery and Pharmacy. Trained in general and vascular surgery, Dr. Carmona also completed a National Institutes of Health-sponsored fellowship in trauma, burns, and critical care. Dr. Carmona was then recruited jointly by the Tucson Medical Center and the University of Arizona to start and direct Arizona's first regional trauma care system. He went on to become the chairman of the State of Arizona Southern Regional Emergency Medical System, a professor of surgery, public health and family and community medicine at the University of Arizona, and the Pima County Sheriff's Department surgeon and deputy sheriff. He is also a Fellow of the American College of Surgeons. Dr. Carmona's interest in public health stemmed from the realization that most of his patients' illnesses and injuries were completely preventable. In 2002 Dr. Carmona was nominated by the president and unanimously confirmed by the United States Senate to become the 17th Surgeon General of the United States. Dr. Carmona was selected because of his extensive experience in public health, clinical sciences, health care management, preparedness, and his commitment to prevention as an effective means to improve public health and reduce health care costs while improving the quality and quantity of life. As Surgeon General, Dr. Carmona focused on prevention, preparedness, health disparities, health literacy, and global health to include health diplomacy. He also issued many landmark Surgeon General Communications during his tenure, including the definitive Surgeon General's Report about the dangers of second-hand smoke.

Marvin J Slepian, MD

Marvin J. Slepian, M.D. is Professor of Medicine (Cardiology), Director of Interventional Cardiology and Director of the Tissue Engineering Lab at the University of Arizona. Dr. Slepian completed his Internal Medicine training at NYU-Bellevue in New York where he was a Resident and Chief Resident in Medicine. He completed his Cardiology training at Johns Hopkins where he was a Clinical and Research Fellow. He completed a second fellowship in Interventional Cardiology at Cleveland Clinic. Dr. Slepian has conducted extensive research, development and pre-clinical investigation of novel cardiovascular therapeutic methods and devices, and is the holder of more than 25 issued and 41 filed patents. He is an expert in polymeric biomaterials and local drug delivery. Dr. Slepian has founded numerous medical device companies, including Focal (NASDAQ-traded, acquired by Genzyme), Endotex, Angiotrax and Hansen Medical, and has served as acting CEO and Board Member of several medical device startups. He earned his A.B. in Biochemical Sciences and Science in Human Affairs from Princeton University, and his M.D. from the University of Cincinnati College of Medicine. He has received additional post-doctoral training at MIT and Washington University.

Jonathan T. Schilling

Jonathan is retired from a 30-year career in the sale and marketing of employee benefit medical/dental plans for Blue Cross and Delta Dental. He received a BS in Information Science Management from the University of San Francisco. He is an active investor and recently invested in NuvOx and led a portion of the round totaling $1.6 Million from a group of investors. His previous investments have included Schilling Robotics (President, Tyler Schilling, Jonathan's brother), which sold in 2012 at a total valuation of several hundred million dollars. The result was an ROI of 22x for the Unit A investors. Jonathan has known Evan Unger since 1969 (high school) and now resides in San Francisco.